Erlotinib (Tarceva) is a human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Some patients who have received it have had gastrointestinal perforations, with fatalities reported.
Chemical type: quinazolinamine
Approved for: advanced non-small cell lung cancer, pancreatic cancer. It has been investigated in additional tumors (renal, gynecologic, etc.)
Risk factors for GI tract perforation:
(1) high dose erlotinib therapy
(2) peptic ulcer disease
(4) concurrent therapy with anti-angiogenic agent
(5) concurrent taxane-based therapy
(6) corticosteroid therapy
(7) NSAID therapy
The drug should be discontinued if a gastrointestinal tract perforation occurs (absolute contraindication to further therapy).
To read more or access our algorithms and calculators, please log in or register.
Purpose: To identify risk factors for gastrointestinal perforation in a patient being treated with erlotinib (Tarceva).
Specialty: Hematology Oncology, Gastroenterology
Objective: risk factors, adverse effects